KRAS and cancer: One is to target the immunogenic somatic mutations unique to individual patient’s cancer, ideally using T cells with memory-progenitor CD39- stem-like phenotype; second is to generate a library of TCRs against shared cancer mutations from common oncogenes such as those in KRAS and TP53.